Cargando…
Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker
SUMMARY: Annual intravenous administration of zoledronic acid is used in the treatment of osteoporosis. A mathematical model was developed to predict bone mineral density up to 2 years after two annual doses of zoledronic acid from the early values of a bone resorption marker in osteoporosis patient...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948273/ https://www.ncbi.nlm.nih.gov/pubmed/29423715 http://dx.doi.org/10.1007/s00198-018-4376-1 |
_version_ | 1783322515479724032 |
---|---|
author | Mori, Y. Kasai, H. Ose, A. Serada, M. Ishiguro, M. Shiraki, M. Tanigawara, Y. |
author_facet | Mori, Y. Kasai, H. Ose, A. Serada, M. Ishiguro, M. Shiraki, M. Tanigawara, Y. |
author_sort | Mori, Y. |
collection | PubMed |
description | SUMMARY: Annual intravenous administration of zoledronic acid is used in the treatment of osteoporosis. A mathematical model was developed to predict bone mineral density up to 2 years after two annual doses of zoledronic acid from the early values of a bone resorption marker in osteoporosis patients. INTRODUCTION: The measurement of bone mineral density (BMD) has been used as a surrogate marker instead of the observation of incident fractures to detect the efficacy of treatment. However, this method requires a long time to obtain significant changes. On the other hand, bone resorption markers respond to bone resorption inhibitors within a few weeks. Therefore, the aim of this study was to develop a mathematical model predicting long-term BMD after two annual doses of zoledronic acid (ZOL) using the early response of a bone resorption marker in osteoporosis patients. METHODS: The model was constructed using 3410 tartrate-resistant acid phosphatase 5b (TRACP-5b) serum concentrations and 1146 lumbar spine (L2-L4) BMD values from 306 patients with primary osteoporosis. A mathematical model was developed to describe the time-dependent profiles of TRACP-5b and BMD. RESULTS: The percentage changes from baseline of the BMD (%BMD) at up to 2 years were predicted from patients’ baseline BMD and baseline and 12-week TRACP-5b values by the model obtained. The simulated 90% prediction interval almost covered the observed %BMD distribution at each time point, and the predictions were comparable to the observed %BMD. CONCLUSIONS: This is the first model to predict BMD for up to 2 years following two annual doses of ZOL using patients’ background characteristics and the early response of TRACP-5b. This model allows us to inform patients at the initial stage of ZOL treatment of their predicted response to treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-018-4376-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5948273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-59482732018-05-17 Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker Mori, Y. Kasai, H. Ose, A. Serada, M. Ishiguro, M. Shiraki, M. Tanigawara, Y. Osteoporos Int Original Article SUMMARY: Annual intravenous administration of zoledronic acid is used in the treatment of osteoporosis. A mathematical model was developed to predict bone mineral density up to 2 years after two annual doses of zoledronic acid from the early values of a bone resorption marker in osteoporosis patients. INTRODUCTION: The measurement of bone mineral density (BMD) has been used as a surrogate marker instead of the observation of incident fractures to detect the efficacy of treatment. However, this method requires a long time to obtain significant changes. On the other hand, bone resorption markers respond to bone resorption inhibitors within a few weeks. Therefore, the aim of this study was to develop a mathematical model predicting long-term BMD after two annual doses of zoledronic acid (ZOL) using the early response of a bone resorption marker in osteoporosis patients. METHODS: The model was constructed using 3410 tartrate-resistant acid phosphatase 5b (TRACP-5b) serum concentrations and 1146 lumbar spine (L2-L4) BMD values from 306 patients with primary osteoporosis. A mathematical model was developed to describe the time-dependent profiles of TRACP-5b and BMD. RESULTS: The percentage changes from baseline of the BMD (%BMD) at up to 2 years were predicted from patients’ baseline BMD and baseline and 12-week TRACP-5b values by the model obtained. The simulated 90% prediction interval almost covered the observed %BMD distribution at each time point, and the predictions were comparable to the observed %BMD. CONCLUSIONS: This is the first model to predict BMD for up to 2 years following two annual doses of ZOL using patients’ background characteristics and the early response of TRACP-5b. This model allows us to inform patients at the initial stage of ZOL treatment of their predicted response to treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-018-4376-1) contains supplementary material, which is available to authorized users. Springer London 2018-02-08 2018 /pmc/articles/PMC5948273/ /pubmed/29423715 http://dx.doi.org/10.1007/s00198-018-4376-1 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Mori, Y. Kasai, H. Ose, A. Serada, M. Ishiguro, M. Shiraki, M. Tanigawara, Y. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker |
title | Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker |
title_full | Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker |
title_fullStr | Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker |
title_full_unstemmed | Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker |
title_short | Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker |
title_sort | modeling and simulation of bone mineral density in japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948273/ https://www.ncbi.nlm.nih.gov/pubmed/29423715 http://dx.doi.org/10.1007/s00198-018-4376-1 |
work_keys_str_mv | AT moriy modelingandsimulationofbonemineraldensityinjapaneseosteoporosispatientstreatedwithzoledronicacidusingtartrateresistantacidphosphatase5baboneresorptionmarker AT kasaih modelingandsimulationofbonemineraldensityinjapaneseosteoporosispatientstreatedwithzoledronicacidusingtartrateresistantacidphosphatase5baboneresorptionmarker AT osea modelingandsimulationofbonemineraldensityinjapaneseosteoporosispatientstreatedwithzoledronicacidusingtartrateresistantacidphosphatase5baboneresorptionmarker AT seradam modelingandsimulationofbonemineraldensityinjapaneseosteoporosispatientstreatedwithzoledronicacidusingtartrateresistantacidphosphatase5baboneresorptionmarker AT ishigurom modelingandsimulationofbonemineraldensityinjapaneseosteoporosispatientstreatedwithzoledronicacidusingtartrateresistantacidphosphatase5baboneresorptionmarker AT shirakim modelingandsimulationofbonemineraldensityinjapaneseosteoporosispatientstreatedwithzoledronicacidusingtartrateresistantacidphosphatase5baboneresorptionmarker AT tanigawaray modelingandsimulationofbonemineraldensityinjapaneseosteoporosispatientstreatedwithzoledronicacidusingtartrateresistantacidphosphatase5baboneresorptionmarker |